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Acute liver failure 
Acute liver failure (ALF) is a clinical syndrome characterized by an acute insult to the liver leading to 
severely impaired liver function with coagulopathy due to hepatocyte necrosis and the development 
of hepatic encephalopathy (HE) (1, 2). This occurs with no preexisting liver disease in contrast to 
patients suffering from acute on chronic liver failure. ALF was initially described in 1946 and further 
defined by Trey and Davidson in 1970 as a “potentially reversible condition, the consequence of 
severe liver injury, with an onset of hepatic encephalopathy within eight weeks of the appearance of 
the first symptoms and in the absence of pre-existing liver disease” (3).  Today, the preferred 
categorization introduced by O`Grady et al. in 1993 (4) takes into account the time interval between 
onset of symptoms, defined as the appearance of jaundice, and the development of encephalopathy 
(HE) (table 1). Clinically this association has important prognostic implications. This time interval can 
also provide indications on the etiology of hepatic failure (i.e paracetamol more often causes 
hyperacute liver failure while idiosyncratic drug reactions often cause sub-acute liver failure (5)).  
 
 Hyperacute Acute Subacute 
Prognosis Moderate Poor Poor 
Duration of jaundice 0-7 days 8-28 days > 28 days 
Cerebral edema Common Common Infrequent 
Encephalopathy Yes Yes Yes 
Prothrombin time Prolonged Prolonged Least prolonged 
Bilirubin Least raised Raised Raised 
 
Table 1 Categorization of ALF. 
 
ALF is a rare disease with incidence of less than 10 cases per million per year in the industrialized 
world (6, 7). Intoxication with paracetamol (acetaminophen) has been the single most frequent 
etiological factor for the development of ALF in the Western world (5, 8, 9), while viral hepatitis type 
A and E are the major causes in the developing world (6, 10). Intoxication caused by paracetamol has 
decreased in the UK since 1998, and the overall survival from ALF has increased from 17 % in the 
time period 1973 – 1978 to 62 % in the time period 2004 – 2008. This has mainly been due to early 
referral to tertiary centers,  improved intensive care treatment and increased use of emergency liver 
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transplantations  (7). Overall survival from ALF in the USA now exceeds 65 %, with a spontaneous 
recovery rate of 40 % (5). 
 
 
Figure 1 Systemic manifestations of ALF.  
Reprint with permission: Shawcross DL, Wendon JA, The neurological manifestations of acute liver failure, Neurochemistry 
International 2012;60(7):662-71 
 
ALF leads to multiorgan failure (MOF) (6), making the treatment challenging (figure 1). Today the 
major cause of death is the development of MOF triggered by a systemic inflammatory response 
syndrome (SIRS) with or without manifest infection (5). The acute liver necrosis leads to release of 
pro-inflammatory cytokines, and exceeds the regenerative capacity of the liver precipitating the 
development of the clinical ALF syndrome (11). Fulfilled SIRS criteria worsens the prognosis and are 
strongly linked to the progression of encephalopathy (12).   




Figure 2 Representation of how MOF develops in ALF.   
Reprint with permission: Larsen FS, Bjerring PN, Acute liver failure, Curr Opin Crit Care 2011;17(2):160-4 
 
Patients with ALF develop a hyperdynamic circulatory state with systemic arterial vasodilation due to 
reduced precapillary sphincter tone leading to low peripheral resistance. Cardiac output is increased 
causing a high output low resistance state (13) (figure 2). Hemodynamic changes also include 
increased portal pressure, splanchnic sequestration of blood and decreased venous return, although 
not as pronounced as in patients with liver cirrhosis (5, 8, 14).  
ALF patients develop disturbances in the coagulation system due to reduced production of 
coagulation factors and accompanying loss of platelets (5, 15), and altered fibrinolytic activity (16, 
17). An increased international normalized ratio (INR) is also a determinant of prognosis.  
Failure of the liver also leads to hormonal and metabolic disturbances such as adrenal insufficiency, 
hypoglycemia and reduced lactate and ammonia clearance (18, 19). Glucose homeostasis is impaired 
due to impaired gluconeogenesis. Lactate levels are increased due to both increased production 
(impaired microcirculation) and decreased clearance (Cori cycle). Lactate also serves as a prognostic 
marker in patients with paracetamol-induced ALF (20, 21). General muscle catabolism is seen in ALF 
and can have impact on ammonia removal by skeletal muscle. An association between ALF and acute 
pancreatitis has also been reported (22).  
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Furthermore, impaired immune function shown by increased susceptibility to infections and 
dysfunction of neutrophils have been found in ALF patients (23). The presence of infection is 
associated with progression of encephalopathy and increased mortality (12, 24).  
Renal failure due to hypotension and acute tubular necrosis (13) is common in ALF (25), with an 
incidence near 50 % (5, 26). The development of renal dysfunction is associated with worsened 
prognosis (27), and the presence of SIRS has been found to be predictive for the development of 
acute renal dysfunction in patients with non-paracetamol induced ALF (28). In ALF caused by 
paracetamol intoxication, the toxicity of the drug itself can also contribute to the development of 
renal dysfunction (5, 13).  
Respiratory dysfunction is uncommon in the early phase of ALF, but acute lung injury can develop 
and often associated with sepsis (6). Severe lung injury can also present as adult respiratory distress 
syndrome (ARDS) (13), with a prevalence of 21 to 30 percent in patients with ALF (5, 29).  
Ventilatory support can, however, be required due to high grade (III-IV) HE rather than respiratory 
failure itself, especially in the early phase of the disease (26). Close monitoring of the conscious level 
in ALF is mandatory as the development of HE is the key element defining its progression from acute 
liver injury to acute liver failure and defines prognosis (7, 30). In the setting of ALF progressing to HE 
grade III and IV, Glasgow Coma Scale can provide more clinically relevant information regarding the 
neurological status of the patient, and is often preferred for continuous evaluation (31). The 
development of HE grade III and IV necessitates endotracheal intubation to protect the airways and 
secure optimal oxygenation and ventilation (5). 
Historically, the development of intracranial hypertension (ICH) due to brain edema has been present 
in around 80 % of patients with ALF (32), and represented the main cause of death (33). A 
retrospective study by Jalan et al. from 2003 found the mortality due to brain herniation to be 35 %, 
frequently in relation to multi organ failure (30). Recently, the incidence of ICH was found to be 
reduced to 20 % in a large study from Kings College. Number of deaths due to cerebral herniation 
(CH) was substantially reduced, which may in part explain the improvements in overall survival (7). 
However, a mortality rate of 55 % in patients developing ICH warrants the development of new 
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Pathophysiology of hepatic encephalopathy in acute liver failure  
Intracranial hypertension in ALF 
HE, originally described by Sherlock et al. (34), is graded from I to IV and encompasses a wide 
spectrum of neurological symptoms ranging from mild cognitive impairment and confusion, to stupor 
and coma (35). The development of HE of any degree represents a major deterioration in the clinical 
state and defines the progression from acute liver injury (ALI) to ALF (36). It is a prognostic factor (37-
39) and its grade correlates with outcome (13). HE is categorized in three different types (A-C) based 
on the underlying pathology, with encephalopathy associated with ALF defined as type A (35). HE in 
ALF is characterized by a potentially rapid progression to ICH due to brain edema.  
Brain edema has been demonstrated to be closely linked with ICH in ALF since an increase in brain 
water tissue has been observed in both animal models and in patients (32). The development of 
cerebral swelling in the setting of acute hepatic necrosis was initially described by Ware et al. in 1971 
and further evaluated in animal models (40, 41). Brain edema is found in both ALF and acute-on-
chronic liver failure (42), but studies in patients with cirrhosis suggest a low grade edema with the 
clinical picture of rapid developing edema and death from ICH being far less frequent than in ALF (43, 
44). Furthermore, patients presenting with hyper acute liver failure more often develop brain edema 
compared to acute and sub-acute liver failure (5), emphasizing the relevance of  the time course in 
this disease.  
ICP is dependent on brain tissue volume, cerebrospinal fluid (CSF) volume and cerebral blood 
volume. Any change in one of these factors will lead to a compensatory change in either of the two 
other factors, known as the Monro-Kellie doctrine (45). As disturbances in any of these factors can 
result in increased ICP, all three factors are closely regulated to maintain an ICP within 7 – 15 mmHg. 
There is a non-linear relationship between brain volume and ICP that allows the brain volume to 
increase to a certain point before ICP begins to rise (figure 3B). At this point exponential relationship 
exists between brain volume and ICP due to the non-compliant and rigid scull (46). ICP between 20 
and 25 mmHg has been shown to affect outcome in patients with head injuries (47), and with ICP 
above 25 compensatory mechanisms do not longer provide sufficient protection to avoid substantial 
elevations in ICP.  
Although the incidence of CH has decreased, the development of ICH remains a major clinical 
challenge, especially in the absence of liver transplantation as definitive treatment. Interventions to 
prevent and treat brain edema in patients with HE is still an unmet clinical need (36, 48). Brain tissue 
comprises 80 percent of the intracranial volume (figure 3A), and elucidating the mechanisms behind 
the development of brain edema is important (32).   





Figure 3 A) Cerebral constituents and their contribution to intracranial volume. (B) Relationship between brain volume 
and intracranial pressure: points A (healthy individuals) B: a certain increase in brain volume does not lead to an increase 
in ICP; points B-C: exceeding the brain volume capacity leads to an increase in ICP as observed in ALF; points B-D: due to 
brain atrophy or alterations in brain volume constituents, a further increase in brain volume is required in order to 
initiate an increase in ICP.  
Reprint with permission: Bosoi CR, Rose CF, Brain edema in acute liver failure and chronic liver disease: similarities and 
differences, Neurochemistry International 2013;62(4): 446-57 
 
Vasogenic and cytotoxic brain edema 
Klatzo defined brain edema as “an abnormal accumulation of fluid associated with volumetric 
enlargement of the brain” and divided it into two different forms; vasogenic and cytotoxic brain 
edema. This categorization was based on the presence of vessel injury leading to escape of water and 
plasma constituents into the surrounding brain tissue, or undisturbed vascular permeability (49). 
Brain edema represents a final common path for several pathological states in the brain, including 
metabolic encephalopathies such as HE (50). This results in a net increase of brain water content and 
can consequently affect the overall brain volume.  
Cytotoxic edema is caused by metabolic disturbances primarily in astrocytes (soma and processes), 
which are important cells in brain water regulation (46, 51). These alterations lead to water transfer 
across the cellular membrane due to osmotic forces, possibly through aquaporins (51, 52). This 
results in an intracellular swelling of the astrocytes due to shift of water from extracellular space to 
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intracellular space. This can be induced by metabolites such as ammonia and lactate (51), and can 
affect both grey and white matter (46).  
Vasogenic edema is a result of increased permeability of the vascular cells comprising the blood brain 
barrier (BBB). This can lead to increased extravasation of water and osmolytes to the extracellular 
space due to hydrostatic pressure forces (51).  
Blood brain barrier 
The blood brain barrier is a barrier between the vasculature of the brain and the microenvironment 
of the neurons. It is of vital importance in order to make a stable microenvironment for the neurons 
to allow them to function properly (53, 54), and prevents blood constituents such as amino acids, 
hormones, H+/K+ and cytokines from disturbing neurotransmission.  
The neurovascular unit of the CNS consists of neurons, endothelial cells, astrocytes and pericytes 
with the basal lamina. This unit is involved in cerebral blood flow regulation and can influence the 
permeability of the BBB (53, 55). The endothelial cells lining cerebral micro-vessels are wrapped 
upon themselves constituting a network through tight junctions (figure 4). An intercellular barrier is 
made, preventing free para-cellular diffusion of molecules except for gases and lipid soluble 
compounds. This leaves much of the cellular transport of substances as glucose, amino acids and 
other charged molecules dependent on trans-cellular routes and specific transporter systems in the 
absence of fenestrations (53). Important constituents of tight junctions are the transmembrane 
proteins occludin, claudin-3 and 5 and junction adhesion molecules (JAMs) (56). These proteins have 
recently attracted attention as important modulators of permeability of the BBB.  
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Figure 4  The cell associations at the BBB. The cerebral endothelial cells form tight junctions at their margins which seal 
the aqueous paracellular diffusional pathway between the cells.  
Reprint with permission: Abbott NJ, Patabendige AA, Structure and function of the blood-brain barrier, Neurobiology of 
Disease 2010;37(1):13-25  
 
Glia cells consist of fibrous (white matter) and protoplasmic (grey matter) astrocytes, oligodendroglia 
and microglia (resident macrophages in the brain). Astrocytic end feet form a network that attaches 
on to the endothelial lining of the vessels (figure 4).  They have an important regulatory role of the 
BBB through induction of new tight junctions and by modulating the transport of substances across 
the BBB. Additionally they provide the cellular link to the neurons (51, 53).  
BBB breakdown enables water and solutes as plasma proteins freely to move into the brain 
parenchyma (extracellular space) driven by the systemic blood pressure (51).  
Brain edema seen in ALF is characterized by astrocytic swelling and has therefore been considered 
mainly to be of cytotoxic origin. Permeability changes have been observed, but the BBB has been 
found histologically intact (57, 58). One of the few histopathological studies performed looking for 
BBB changes in ALF was a post mortem study showing primarily an intact BBB with no convincing 
signs of BBB breakdown (59). Increased permeability for large molecules in ALF has however been 
observed, and ammonia was shown to be a possible cause for this increase (60, 61).  
We have learned from earlier work with our pig model that ICP is raised with evidence of brain 
edema revealed by brain water measurements (62). Furthermore, several other studies have 
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confirmed the presence of regional differences of brain edema (62-64). However, ultrastructural 
changes in different brain regions in a large animal model had, to our knowledge, not been 
investigated before.   
Ammonia 
The development of brain edema in ALF is today considered to be multifactorial, displaying a 
synergistic effect of ammonia, systemically and brain derived inflammation and impaired cerebral 
auto-regulation (55, 65, 66). However, the important role for ammonia in the pathophysiology of ALF 
remains undisputed and has been the focus for this thesis.  
In aqueous solutions ammonia (NH₃) forms a reversible conjugation pair with the ammonium ion 
(NH₄⁺) with pKₐ 9.3. At physiological pH about 98% is kept in the ionized form NH₄⁺ (67). Ammonia 
(NH₃) diffuses freely across cell membranes and the ammonium (NH₄⁺) with similar ionic 
characteristics as K⁺, can be transported across membranes via K⁺ - transporters and channels (68, 
69).  
A correlation between ammonia and brain edema has been substantially proven in several animal 
models of ALF (62, 70-72). Clemmesen et al. were the first to correlate arterial ammonia to the 
incidence of cerebral herniation (CH) in humans. They found arterial ammonia levels of more than 
146 μM within 24 hrs after the development of HE grade III to be predictive of CH, and observed 
increased cerebral ammonia uptake with increasing arterial ammonia levels (73). The relation 
between ammonia on admission and later cerebral complications was confirmed by Bernal et al. with 
ammonia concentration being an independent risk factor for the development of HE and ICH. They 
found that arterial ammonia levels of 200 μM  were predictive of ICH in patients with established ALF 
and HE (38). In a study of ALF from mainly viral causes and with no ammonia lowering therapy or use 
of liver transplantation, a cut-off value of 124 μM measured on admission to hospital was found to 
be a predictor for outcome and the development of cerebral edema (74). Kumar et al. found 
persistent hyperammonemia to predict higher mortalilty and incidence of cerebral edema (75), and 
Kundra et al. found plasma ammonia levels to correlate with severity of HE and ICH (76). 
Furthermore, patients with urea cycle enzyme deficiency can develop cerebral edema without having 
liver insufficiency other than impaired detoxification of nitrogen (77).  
Brain ammonia is derived from diffusion from blood and endogenous pathways from glutamine, 
glutamate and aspartate metabolism (78). Arterial blood ammonia is the major determinant of brain 
ammonia uptake (79, 80), and net ammonia uptake from blood to brain has been shown in several 
human studies both in normal state and hyperammonemic state (73, 81-84).  




Nitrogen containing molecules are under strict regulation in the body. Nitrogen is important in a 
number of synthetic pathways and reactions, but its metabolic product ammonia is toxic to the brain 
necessitating a strict regulation to maintain homeostasis (67, 85). Ammonia is transported from 
peripheral organs to the liver as glutamine or alanine. The liver is the only organ containing the 
complete enzymatic machinery for urea production and thereby net excretion of nitrogen (86). 
Ammonia is furthermore derived from the gut by bacterial degradation and catabolism of amino 
acids, proteins and nucleic acids.  
Ammonia can be fixed into metabolic molecules, such as amino acids, through the reactions of 
different enzymes including glutamate dehydrogenase (GDH), glutamine synthetase (GS) and 
carbamoyl phosphate synthetase (87). The latter captures ammonia for processing in the urea cycle, 
producing urea as the non-toxic excretion product of nitrogen. However, in the setting of diminished 
urea synthesis capacity the first two pathways are of pivotal importance.  
GDH incorporates ammonia by direct amination of α-ketoglutarate yielding glutamate (figure 5). GS 
amidates glutamate; taking up free ammonium for the production of glutamine (figure 6). GS is a 
cytosolic enzyme located in perivenous hepatocytes and in several other organs such as muscle, 
kidney and brain. In the liver it functions as an ammonia scavenger for any ammonia escaping the 
periportal urea synthesis. Both reactions can potentially incorporate ammonia in the presence of 




Figure 5 Glutamate dehydrogenase reaction.  
Reprint with permission: Adeva MM, Souto G, Ammonium metabolism in humans, Metabolism: clinical and experimental, 
2012;61(11):1495-511 
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Figure 6 Glutamine synthetase reaction (GS).   
Reprint with permission: Adeva MM, Souto G, Ammonium metabolism in humans, Metabolism: clinical and experimental, 
2012;61(11):1495-51 
   
The enzyme glutaminase is responsible for the removal of the amide group from glutamine yielding 
glutamate and ammonium (figure 7). This is a mitochondrial enzyme that is expressed in several 
tissues including liver, brain, kidney and small intestines (67).  
 
 
Figure 7 Glutaminase reaction.  
Reprint with permission: Adeva MM, Souto G, Ammonium metabolism in humans, Metabolism: clinical and experimental, 
2012;61(11):1495-511 
 
GS and glutaminase reactions play important roles in interorgan nitrogen homestasis.    
Amino acids and ammonia metabolism 
Muscle turnover and breakdown of ingested amino acids are the primary sources of free amino acids. 
The body has no storage for amino acids and the supply for metabolic reactions must constantly be 
adjusted to the demands or degraded and excreted (88). The biggest pool of free amino acids is 
confined to the intracellular compartment (89). Plasma amino acid concentrations therefore do not 
necessarily provide information on the overall amino acid balance in disease states. However, the 
plasma free amino acid content is important in ensuring a continuous availability of free amino acids 
for nitrogen containing reactions.  
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Transport of amino acids across cell membranes is mediated by Na+ coupled active transport 
mechanisms against a concentration gradient (87). Therefore, the overall energy state of the cell can 
influence on the amino acids concentration.  
In transamination reactions the amino group is transferred from an amino acid to an α-ketoacid 
catalysed by a transaminase. These reactions are readily reversible, and do not change the overall 
balance of free ammonium since the amino groups are only switching to another carbon skeleton.  
Oxaloacetate-aspartate, pyruvate-alanine and branched chain amino acids (BCAA) –branched chain 
keto acids switch amino groups in a coupled reaction with α-ketoglutarate-glutamate (figure 8). 
Glutamate then acts as a donor of amino groups for further synthetic and excretions pathways. 
Oxaloacetate and α-ketoglutarate are both intermediates in the tricarboxylic acid cycle (67).  
 
 
Figure 8 Aminotransferases reaction. ALT: alanine aminotransferase; AST: aspartate aminotransferase; BCAA: branched-
chain amino acids; BCAT: branched-chain amino acids aminotransferase; BCKA: branched-chain keto acids.   
Reprint with permission: Adeva MM, Souto G, Ammonium metabolism in humans, Metabolism: clinical and experimental, 
2012;61(11):1495-511 
 
Glutamate has an important position in the general amino acid metabolism as a receiver of amino 
groups from other amino acids, through transamination, for further metabolism in the urea cycle 
(86). Furthermore, it serves an important role in interorgan transport through the synthesis of 
glutamine (GS reaction) and transamination to alanine. In normal urea cycle α-ketoglutarate in the 
cytosol of periportal hepatocytes receive amino groups from amino acids forming glutamate. 
Glutamate is then transported into the mitochondria where the ammonia enters the urea cycle. The 
second ammonium molecule is derived from aspartate. In the periphery glutamate is amidated by GS 
forming glutamine that acts as transporter of the ammonia to the liver, preventing an increased 
plasma ammonia concentration.  
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Glutamine is the most abundant amino acid in the body (88). It serves many important functions as 
energy provider for rapid renewed cells like enterocytes and immune cells, and functions as nitrogen 
donor for synthetic reactions. It is also important in the regulation of acid-base balance in the 
kidneys. Glutamine furthermore serves as a non-toxic carrier for ammonia from peripheral organs 
such as skeletal muscle to the liver for nitrogen disposal through the urea cycle. Glutamine is a non-
essential amino acid and is synthesized in the GS reaction (87).  
Alanine is important in the interconnection between carbohydrate metabolism and amino acid 
metabolism through the glucose-alanine cycle. It serves as a transporter of amino groups from BCAA 
metabolism to the liver for further metabolism in the urea cycle. Alanine is formed in the intestines 
by conversion of other amino acids in the enterocytes (87).  
Glycine is a one carbon amino acid that takes part in the synthesis of several molecules such as 
porphyrines and glutathione. It is an inhibitory neurotransmitter in the spinal cord and acts as a 
modulator at the N-methyl –D-aspartate (NMDA) receptor in the frontal cortex (90, 91). It can arise 
through three reactions; the glycine cleavage system, synthesis from serine and trough 
transamination with alanine from glyoxylate (87). Serine is synthesized from 3-phosphoglycerate, an 
intermediate from glycolysis. It undergoes transamination with glutamate as amino group donor. 
Serine can be further converted to pyruvate by serine hydratase.  
Interorgan metabolism of ammonia  
The plasma concentration of ammonia is held within narrow limits (below 65 μM) to prevent toxic 
effects on the brain (67, 92). Interorgan metabolism of ammonia is dictated by the distribution of GS 
and glutaminase (93).  
In the normal state ammonia is being transported to the liver from the intestines and peripheral 
organs for disposal through the urea cycle. The urea cycle is a low affinity-high capacity system for 
detoxification of ammonia through several steps, initialized by carbamoyl-phosphate synthetase in 
periportal hepatocytes. GS in perivenous hepatocytes removes any ammonia escaping from urea 
synthesis. In addition to this, periportal hepatocytes contain  glutaminase which liberates ammonium 
(94). Hence, the liver has the ability to regulate the balance between glutamine breakdown and 
synthesis in an intercellular glutamine cycle within the liver by these two simultaneously active 
reactions (95).   
In the normal state about 50 % of ammonia is generated from intestinal blood derived amino acids 
(96), the rest from colonic bacteria. A substantial ammonia production in germ free animal models 
(absence of colonic bacteria) has been shown, highlighting the importance of amino acid derived 
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ammonia (97).  Enterocytes have a predominantly glutaminase activity as the primary energy source 
for these cells is the deamination of glutamine (98). Ammonia is liberated and glutamate can be 
further transaminated yielding alanine. Portal drained viscera is thus considered to be net ammonia 
liberating organs.  
The kidneys are glutaminase (kidney type) abundant organs, and take up glutamine for energy 
utilization (99) and for pH-regulation releasing about 30 % of the liberated ammonia into the urine. 
Renal uptake of glutamine constitutes about 10-15 % of the body glutamine flux (100). Kidneys 
contain both glutaminase and GS and are capable of both synthesizing and degrading glutamine 
(101). They are considered to be predominantly ammonia producing organs, but can under certain 
conditions shift from net ammonia release into the renal vein to net ammonia excretion by reversing 
to 70 % excretion in urine (100).   
Active muscle produces ammonia through metabolism of amino acids and degradation of proteins. 
Muscle GS produces glutamine for transport of ammonia to the liver, where it is detoxified through 
the urea cycle. Due to its mass relative to other GS containing organs, muscle is probably the main 
glutamine synthesizing organ (100).  
Brain contains both glutaminase and GS. The enzymes are compartmentalized to neurons and 
astrocytes respectively, and their interplay is important in brain energy metabolism and 
neurotransmitter production (78).  
Nitrogen metabolism in acute liver failure 
Circulating level of ammonia in ALF is regulated by the interplay between the failing liver, muscles, 
kidneys, and intestines (102). Acute liver failure leads to abrupt changes in the overall balance of 
amino acids and ammonia in plasma, causing an increased concentration of most amino acids (83, 
103-105). The capacity for urea synthesis is significantly decreased because of diminished amount of 
viable hepatocytes. Furthermore, nitrogen containing blood from the portal vein is partly shunted to 
the systemic circulation, thereby escaping hepatic metabolism. This is in contrast to the situation in 
cirrhotics with acute-on-chronic liver failure where a net removal of ammonia across the liver is seen 
(73). These factors together make the removal of ammonia dependent on alternative routes.  
By virtue of its mass, skeletal muscle becomes the most important organ for removal of excess 
ammonia in hyperammonemia through the action of GS (102, 106). Increased ammonia uptake by 
muscle has been found in patients with ALF (81, 82, 107), although conflicting results have been 
reported in animal models of ALF (108). Furthermore, conflicting observations have been reported 
on whether glutamine efflux from muscle is increased. In a human ALF study ammonia uptake across 
A novel ammonia lowering strategy for the treatment of intracranial hypertension in acute liver failure 
19 
 
the muscle was quantified to 100nm/100g/min which correlated with glutamine production (107). 
Ammonia uptake and glutamine release was also observed in cirrhotic patients with induced 
hyperammonemia (109). Furthermore, an increased GS activity in muscle has been found in ALF 
providing increased capacity for ammonia removal (110). However, increased release of glutamine 
across the muscle can also be due to increased muscle catabolism.  
The kidneys contain both glutaminase and GS making them capable both synthesizing and degrading 
glutamine (102). They can therefore adapt to the body`s acid-base balance and plasma ammonia 
levels. In hyperammonemia a shift from systemic release to an increased excretion of ammonia has 
been observed both in animal models and patients (111, 112). However, in the setting of ALF this 
protective mechanism seems to be overwhelmed (113). The combination of rapidly increasing 
hyperammonemia and decreased renal function results in net systemic release, making the kidneys 
net ammonia producing organs in ALF (96).  
Also the intestines can contribute to the ammonia release in hyperammonemia due to glutaminase 
containing enterocytes. In a study of cirrhotic patients ammonia was released by the portal drained 
viscera and glutamine was taken up (109). However, during a simulated upper gastrointestinal bleed 
the increased arterial ammonia was found to be caused by increased ammonia release by the 
kidneys and not the intestines (112). In ALF, the increased ammonia contribution from portal drained 
viscera is considered to be due to intra and extra-hepatic shunting and not altered ammonia 
production by the gut (102). Taken together, this underlines the important role for kidney glutamine 
metabolism in hyperammonemia.    
These observations have been confirmed in the model of ALF used in this study (114). Hepatic 
devascularisation induced hyperammonemia, and the kidneys were shown to be important 
contributors. Furthermore, portal drained viscera ammonia release did not increase in ALF and 
consumption of glutamine was not affected by devascularisation. Ammonia was not found to be 
taken up by muscle, in accordance to other animal studies (108). However, this model shows 
increased arterial levels of glutamine and decreased levels of glutamate, making it suitable and 
relevant for the present studies (114). 
Due to low tissue mass the brain is quantitatively of minor importance in ammonia removal (102, 
115), but plays a qualitative important role as hyperammonemia may lead to the development of 
brain edema. 
 





Figure 9  In ALF, reduced capacity of urea synthesis leads to hyperammonemia. Gut and kidneys can contribute to this via 
GS activity, which liberates ammonia. Increased circulating ammonia increases glutamine production in the brain, 
leading to astrocytic swelling and brain edema. This can lead to ICH.  
Reprint with permission: Jalan R, Lee WM, Treatment of hyperammonemia in liver failure: a tale of two enzymes, 
Gastroenterology 2009;136(7):2048-51 
 
Ammonia and its effect on the astrocyte 
Under physiological conditions ammonia is transferred between the neuron and the astrocyte via the 
glutamate-glutamine cycle for energy and neurotransmitter production (glutamate, GABA) (85, 116). 
A distinct compartmentalization for glutaminase and GS exists. GS is a predominantly, if not solely an 
astrocytic enzyme (117). GS produces glutamine through the amidation of glutamate. The glutamine 
is then taken up by the neurons and converted to glutamate by glutaminase, which replenishes the 
glutamate neurotransmitter for release from the neuron. Neuron released glutamate is taken up by 
the astrocyte and used to generate glutamine and remove ammonia.   
In hyperammonemia GS becomes an ammonia removal pathway in order to compensate for the 
increased ammonia load to the brain. The brain does not contain the enzymes for urea cycle, leaving 
it dependent on the GS reaction to remove excess ammonia (85). Astrocytic GS is not up-regulated in 
hyperammonemia, as is the case for muscle GS (118). Therefore, this pathway has very little excess 
capacity rendering the brain particularly vulnerable to the adverse effects of hyperammonemia 
(119). The removal of ammonia and generation of glutamine by astrocytes leads to increased 
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intracellular osmolality and hence an obligate shift of water from extracellular to intracellular 
compartment resulting in astrocytic swelling (cytotoxic edema) (77).  
Increased brain glutamine production is seen in brain edema due to hyperammonemia (71, 120), and 
a correlation between brain extracellular glutamine and ICP in persistent hyperammonemia has been 
found in patients with ALF (121).  Furthermore, inhibition of GS has been shown to prevent increased 
cortical glutamine and brain water in hyperammonemic animals (122-124). Astrocytes compensate 
for the increased glutamine production by expelling K⁺ and osmolytes such as glutamate, taurine and 
myo-inositol (57, 125). In accordance with this, studies have shown decreased myo-inositol 
concentration in astrocytes in hyperammonemia and an inverse relation to glutamine. This 
compensation is, however, likely to be insufficient in ALF with rapidly increasing arterial levels of 
ammonia (126).   
Despite the fact that increased intracellular glutamine and astrocytic edema seems to be closely 
related, several studies have shown a lack of correlation between brain glutamine and brain edema 
in ALF suggesting that other potential mechanisms could also be involved (57, 125, 127-129). Rather 
than a steady increased intracellular production, the newly formed glutamine may be prevented 
from leaving the astrocyte due to defect glutamine transporters across the cell membrane, which 
might further increase the osmotic burden on the astrocyte (127). Another hypothesis suggests that 
the pathogenic effect of glutamine is mainly due to a mitochondrial metabolism of glutamine yielding 
ammonia (“Trojan horse-hypothesis”). This induces oxidative stress that can initiate the 
mitochondrial permeability transition reaction leading to cell swelling and energy failure (130). The 
role of oxidative stress induced by ammonia in ALF is well acknowledged (131, 132), even though the 
Trojan horse hypothesis remains debated (77, 133). Either way, a connection between osmotic and 
oxidative stress is indicated, creating a self-amplifying loop triggering downstream consequences 
(134).  
Studies have furthermore indicated that increased intracellular glutamine may act as the signal for 
increasing cerebral blood flow (CBF) in hyperammonemia, linking two major pathophysiological 
mechanisms behind brain edema in ALF (135). 
An increased extracellular glutamate concentration in the brain is also found in several models of 
ALF. This could be due to diminished expression of GLT-1, a glutamate transporter on the astrocyte, 
that can result in a relative NMDA receptor overactivity (136).  
Another study found increased ICP to correlate with increased extracellular glutamine level and 
increased lactate-pyruvate ratio in the brain, indicating an accelerated glycolysis and impaired energy 
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supply in ALF (137). Increased brain and CSF lactate concentrations have consistently been shown in 
hyperammonemia (119), and was found to precede surges of high ICP in patients with ALF (138). 
Furthermore, an association between reduced ICP and attenuated extracellular ammonia and lactate 
was observed in the current model used in this thesis (139). In a rat model of ALF impaired glucose 
metabolism shown by altered lactate metabolism was found to be the major cause of brain edema 
(128, 140).  
In conclusion, the exact mechanisms by which ammonia disrupt the astrocytic homeostastis is not 
yet fully elucidated. Astrocytic swelling is multifactorial and additional mechanisms such as 
upregulated peripheral type benzodiazepine receptor, increased neurosteroid production and 
increased glutathione concentration may also be implicated (123).  
Inflammation and brain edema 
Infection and inflammation evident by the presence of two or more SIRS criteria, increase the risk for 
ICH in ALF (12, 24). ALF is a generalized inflammatory state initiated by the release of damage 
associated molecular patterns (DAMPs) from dying hepatocytes leading to an increased pro-
inflammatory cytokine production (TNF-α, IL-6) and leukocyte recruitment (11, 141). A case report 
describing uncontrollable ICP in a patient with ALF, reported that hepatectomy awaiting the new liver 
reduced ICP and improved hemodynamic parameters. Plasma pro-inflammatory cytokine level 
decreased, while ammonia levels remained elevated  (142). Patients with ALF are functionally 
immunosuppressed. Immuno-paresis during the resolution phase of an inflammatory response 
predisposes to secondary infections (11, 143) which can aggravate ICH. Also, a dysfunction of 
neutrophil leukocytes, which correlates with peak ammonia levels, has been found in ALF similar to 
what has been observed in patients with sepsis (23). The association between inflammation and 
increased ICP in hyperammonemia has also been shown in animal models. In a porcine ALF model 
increased ICP was observed when lipopolysaccharides were administered together with a 
hepatotoxin, but without changing ammonia levels (144). Another study found increased brain 
edema in cirrhotic rats administered lipopolysaccharides. This increase was unrelated to ammonia 
levels (145).  
Both locally (brain) and systemically derived pro-inflammatory mechanisms seem to be involved in 
the development of brain edema (146). Evidence for activation of microglia with increased 
production of pro-inflammatory cytokines has been shown in an animal model (147), and increased 
pro-inflammatory cytokine production in the brain has also been found in patients with ALF (148).  
The impact of inflammation on the BBB has therefore gained interest in explaining the synergisms 
between ammonia, inflammation and cerebral blood flow alterations in ALF (149).  
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Cerebral blood flow 
Cerebral blood flow (CBF) is increased in ALF. This is caused by gradual cerebral vasodilation and 
impaired cerebral autoregulation, and has been reported in both humans and animal models (66, 
150-152). With impaired autoregulation cerebral blood flow fluctuates in parallel with arterial blood 
pressure. Increased CBF has been shown to be associated with brain swelling in hyperammonemia 
(135) and increased ICP in models where inflammation has been induced in the presence of 
hyperammonemia (153). Cerebral blood flow is tightly regulated to avoid fluctuations in cerebral 
perfusion pressure (CPP), and is connected with the metabolic demands of the brain. In the case of 
ALF this coupling seems to be interrupted, resulting in increased blood flow that exceeds the 
metabolic needs of the brain. This has been termed luxury perfusion and is prominent in ALF (154). 
Furthermore, increased CBF has been observed to precede surges in ICP in patients with high grade 
HE. Interestingly, studies indicate that the loss of autoregulation is not caused by ammonia or the 
increased ICP itself, suggesting other factors such as the effects of hepatic necrosis and reduced liver 
mass (155). Increased CBF has been associated with maximal glutamine accumulation in the 
astrocytes, suggesting that other factors than ammonia are important (156). Interestingly, moderate 
hypothermia has been shown to restore cerebral autoregulation in ALF (157). 
In conclusion, a two hit model for the development brain edema and ICH in ALF has been proposed. 
Increased ammonia levels represent the first insult to the brain followed by a synergistic effect of 
inflammation and increased CBF (158, 159).  
Treatment of acute liver failure 
General treatment 
The only definitive treatment for ALF is liver transplantation (160). However, improved supportive 
therapy awaiting spontaneous recovery of liver function has resulted in a survival rate of one third to 
half of the patients without the need for transplantation (21). Medical treatment of ALF seeks to 
provide metabolic and hemodynamic stability to optimize the conditions for spontaneous hepatic 
regeneration and minimize the risk for complications (6). This includes ventilatory support for 
improved oxygenation and airway protection, renal replacement therapy, the use of fluids and 
vasopressors to provide hemodynamic stability and prevention of hypoglycemia. Early administration 
of N-acetylcysteine (NAC) is important to reduce the hepatotoxic effect of paracetamol (161, 162). 
Furthermore, liberal use of empirical broad spectrum antibiotic therapy to patients developing SIRS 
or increasing encephalopathy grade is recommended (163).   
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Treatment of intracranial hypertension 
Current therapeutic interventions for HE in ALF includes mannitol for ameliorating ICP surges, strict 
control of serum sodium and the use of sedatives such as propofol (164) and ammonia clearance 
using hemofiltration (165). Liver replacement therapy has been extensively studied. MARS 
(Molecular Adsorbent Recirculating System) can possibly reduce HE grade and act as a bridge to 
transplantation (166, 167). The use of moderate hypothermia has been studied as a bridge to 
transplantation with encouraging results (48, 84) showing a favorable effect on multiple 
pathophysiological mechanisms. A recent retrospective multicenter study found a positive effect for 
young patients with paracetamol intoxication although there was no difference in overall 21-day 
survival (168).  The mechanisms behind ICP reduction during hypothermia are not fully elucidated, 
but an effect on arterial ammonia and uptake of ammonia in the brain has been observed (84, 169).  
Ammonia lowering treatment 
Ammonia is closely linked to the development of HE and ICH in ALF (38). However, current ammonia 
lowering strategies have not proven to be effective in patients suffering from ALF (26). The classical 
approach to reduce ammonia in liver failure has been directed toward reducing the production of 
ammonia in the gut with non-absorbable disaccharides and non-absorbable antibiotics. The rationale 
for the first intervention is to decrease the transit time and change the pH in order to decrease 
uptake of ammonia across the intestines. Poorly absorbable antibiotics will reduce the urea 
production from urease containing bacteria in the large bowel (170).  
A meta-analysis from 2004 concluded that there was a lack of evidence for the routine use of these 
strategies for the treatment of hepatic encephalopathy (HE) in patients with cirrhosis (171), but later 
studies have shown potential beneficial effect in certain clinical settings (172). In ALF no clinical trial 
has been performed, but preliminary results of a retrospective study from the U.S. liver failure group 
showed no effect of lactulose in ALF (173). It has been shown that a considerable part of intestinal 
derived ammonia is due to increased glutamine breakdown in the small intestines yielding free 
ammonia, contrary to bacterial production in the colon (101). The routine use of lactulose has 
therefore been questioned (37).  
The current understanding of hyperammonemia has led to therapies trying to increase the ammonia 
removal as opposed to decreasing ammonia production by exploiting other organs that are of 
importance, with muscle being the main target. Ornithine and aspartate (LOLA-treatment) increase 
the overall provision of glutamate, thereby providing an increased substrate for glutamine 
production by GS and extra substrate for the remaining urea cycle function (174). LOLA was shown to 
lower plasma and CSF ammonia and prevent brain edema in a rat model of ALF (72). 
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Hyperammonemia, induced by portacaval anastomosis, has been shown to increase GS activity in 
muscle (118, 175). In the study by Rose et al. LOLA treatment further increased GS activity in muscle, 
revealing the important role of skeletal muscles in treating hyperammonemia (72). LOLA was also 
shown to protect against ammonia precipitated coma in a study of portacaval shunted rats (174).  
In ALF ammonia removal is dependent on extrahepatic organs. However, organs containing 
glutaminase, such as the intestines and kidneys are able to re-metabolize glutamine to glutamate 
and ammonia thus creating rebound hyperammonemia. This may occur as the formed glutamine is 
not being removed from the circulation. In 2009 a randomized, controlled study of LOLA vs placebo 
showed no beneficial effect on morbidity or mortality. Also, the mean reduction in ammonia levels 
over 6 days was not significantly different between LOLA and placebo treated groups (176). 
Furthermore, ammonia did not decrease at any time point in this study, which was explained as a 
futile cycling of glutamine between muscle and intestines in the absence of a definitive removal by 
the liver (176). Clemmesen et al. provided further evidence for this relationship as they were able to 
decrease systemic ammonia by removing glutamine using high-volume plasmapheresis (177).  
Treatment of hyperammonemia in children with urea cycle disorders (UCD), by providing non-urea 
dependent pathways for nitrogen removal was initially discovered in 1979 by Brusilow (178). The 
administration of phenylacetate and benzoate increased the removal of glutamine and glycine, 
respectively (179). This has significantly increased survival and decreased morbidity for children with 
UCD (180, 181). Alternative pathway therapy has also previously been studied in liver failure. Sodium 
benzoate was found to be as effective as lactulose for the treatment of acute portosystemic 
encephalopathy (182). However, the risk of depleting glutamate stores in liver failure led to the 
hypothesis of combining ornithine from LOLA-treatment with alternative pathway removal of 
ammonia. This hypothesis was put forward in 2007 by Jalan et al. and initiated the current studies 
(183). It was proposed that the concomitant administration of L-Ornithine and Phenylacetate (OP) in 
acute liver failure would provide a sustained reduction in arterial ammonia concentration through;  
 
1. Increased provision of glutamate by transamination of ornithine for detoxification of ammonia to 
glutamine 
2. Excretion of the glutamine thus formed by conjugation with phenylacetate as    
phenylacetylglutamine in the urine.  
 






Figure 10  The co-administration of L-ornithine and phenylacetate to pigs with ALF stimulates ammonia removal by 
increasing glutamate in the muscle (transamination of ornithine to glutamate) and increasing glutamine production 
through GS. Newly formed glutamine is thus conjugated with phenylacetate and excreted as phenylacetylglutamine 
through the kidneys, preventing a glutamine-induced ammonia rebound effect.  
Reprint with permission:, Ytrebø LM, Kristiansen RG,  L-ornithine phenylacetate attenuates increased arterial and 
extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure, Hepatology 
2009;50(1):165-74 
 
As glutamine contains two nitrogen atoms, the conjugation with phenylacetate would remove two 
waste nitrogen atoms by each phenylacetate molecule, providing a net removal rate equal to the 
urea cycle (184).   






The aim of this study was to describe ultrastructural changes in different parts of the brain in pigs 
with acute liver failure.  
 
Study II 
We wanted to determine whether administration of the newly invented drug Ornithine 
Phenylacetate (OP) could attenuate ammonia in blood and the brain (extracellular fluid) through the 
hypothesized phenylacetylglutamine conjugation pathway, and whether this could modulate the 
increased ICP observed in this model of acute liver failure.  
 
Study III 
Based on the results from study II we wanted to investigate whether other conjugation pathways for 
ammonia could be involved in the ammonia removal reported in study II. We specifically wanted to 
study the impact of OP treatment on the phenylacetylglycine pathway as an additional ammonia-









Methods are described in detail in each of the individual papers included in this thesis. The aim of the 
current section is to provide the reader with a general introduction to the methods applied.   
Pig model 
The study was performed in the Surgical Research Laboratory at UiT - The Arctic University of 
Norway. Animal experiments were approved by the Norwegian Experimental Animal Board. The pigs 
were kept in the animal department for at least 2 days before the experiments. The animals were 
looked after by the veterinarian care service and the general health conditions were continuously 
monitored prior to the experiments. The conditions in the animal room were strictly controlled to 
reduce stress for the animals.  
A well-characterized and highly reproducible large animal model which recapitulates the cardinal 
features of human ALF was used (185). The model is a hepatic devascularized model of acute liver 
failure (portacaval shunt + hepatic artery ligation). We induced a hepatic insult mimicking the initial 
(hyper acute) phase of ALF. It provides a therapeutic window of 8 hours which makes it suitable for 
testing interventions which could potentially modulate the early course of disease. We have focused 
our experiments on studying end organ dysfunction in acute liver failure and both in vivo and in vitro 
methods have been applied.  
We defined T = - 30 minutes as the time when all catheters were in place, but before ALF induction. T 
= 0 hour was defined as the time of ALF induction or completion of sham surgery. All in vivo 
experiments were terminated at T=8 (animals sacrificed) and samples harvested for further in vitro 
studies.    
Pigs with acute liver failure induced by hepatic devascularization develop a hyperdynamic circulation 
with increased cardiac index and decreased systemic vascular resistance index. Hyperammonemia  
and ICH (186), together with increased liver enzymes and signs of coagulopathy develop rapidly 
(185).  
Animal preparation 
The pigs were anesthetized with soidum thiopenthal, fentanyl and midazolam. The anesthesia was 
stopped after the induction of liver failure. Level of anesthesia was regularly examined and boluses 
given as required. All animals were tracheotomised and ventilated using a volume controlled modus 
adjusted by means of repeated arterial blood gas analyses. They were kept normothermic, defined as 
38.5 ± 1˚C (187). ALF was induced with an end-to-side portacaval shunt followed by ligation of the 
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hepatic arteries at T = 0 h and monitored for 8 hrs (185). All animals received NaCl 9 mg/ml 
containing glucose as a preoperative load, and a continuous infusion with normal saline during the 
experiment. After ALF induction, glucose and human albumin (200 mg/ml) were continuously 
infused, with sham-operated animals receiving only half the amount of glucose in order to render the 
glucose levels comparable between the groups. All animals received equal amounts of intravenous 
fluids during the experiments.  
The animals were invasively monitored by means of a pulmonary artery catheter and a femoral 
artery catheter. A central venous catheter was inserted for the administration of fluids and study 
medications. An intraparenchymatous ICP-transducer was used for continuous measurement of 
intracranial pressure. A second burr hole was made for a microdialysis catheter. Cardiac output, 
cardiac index and cerebral perfusion pressure were calculated based on continuous measurements. 
Arterial and venous blood was drawn every second hour and frozen for later analysis. Venous arterial 
differences were calculated as the difference between venous and arterial concentrations of the 
actual substance. Microdialysate was collected every hour and frozen for later analysis. The urine 
bladder was drained via a cystotomy and urine was collected hourly.  
Methods related to paper I 
Brain biopsies 
A craniectomy was performed and brain biopsies were obtained from frontal cortex, brain stem and 
cerebellum at T=8. Samples were fixated on McDowell fixation liquid for further analysis by light 
microscopy and electron microscopy.  
Electron microscopic examination of brain biopsies 
We performed a semi-quantitative evaluation of ultrastructural changes of the brain samples. Prior 
to ultrastructural examination, semi-thin sections for light microscopic examinations were performed 
and areas of interest for further studies by transmission electron microscopy were subsequently 
defined. Areas with visible artifacts were excluded prior to ultrastructural examination. The severity 
of ultrastructural changes was graded according to an established scoring system based on well 
acknowledged ultrastructural criteria (Tables I–III, paper I) (188-190). The more pronounced changes 
in each biopsy specimens were selected for each scoring. All sections on electron microscopic 
pictures were blinded for the investing pathologist. From each pig we selected eight micrographs 
from each region, which were examined and scored. 
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Methods related to paper II and III 
Administration of study medication 
L-ornithine was administered intravenously at a dose of 0.07 g/kg/hour. Phenylbutyrate (pro-drug for 
phenylacetate) was administered at a dose of 0.05 g/kg/hour via an oro-duodenal catheter. Correct 
catheter position was confirmed during the laparotomy. Medication was administered as a 
continuous infusion for the duration of the experiment, and normal saline was used as vehicle in 
both the ALF and sham groups.  
Arterial ammonia 
Ammonia was analyzed according to the method described by Neeley et al. (191) using an ammonia 
assay reagent kit (AA0100) supplied by Sigma Aldrich (St. Louis, MO, USA). The method is based on an 
enzymatic reaction between ammonia in the sample, α-ketoglutarate and reduced nicotinamide 
adenine dinucleotide phosphatase (NADPH) in the presence of L-glutamate dehydrogenase. The end 
products in the reaction are L-glutamate, water and oxidized nicotinamide adenine dinucleotide 
phosphatase (NADP+). The formation of NADP+ decreases the sample absorbance at 340nm and this 
decrease is proportional to the concentration of ammonia in the sample.  
Extracellular ammonia in brain microdialysate 
Microdialysis is based on dialysate sampling of molecules of interest by a semipermeable membrane 
induced by concentration differences across the membrane. It can be used for measuring 
extracellular concentrations of endogenous and administered molecules, and it allows for continuous 
measurements over several hours (192).  We applied this method to measure the extracellular 
concentration of ammonia in the brain. Ammonia in microdialysate was analyzed with the same 
method as for arterial ammonia measurements. 
Biopsies from brain and muscle 
Brain biopsies and muscle biopsies were harvested at T=8 and immediately frozen (freeze clamp 
technique at -80˚C) for the measurement of amino acids and urea. 
Amino acids and urea in blood and tissue from brain and muscle 
For the identification and quantification of amino acids in blood, brain microdialysate and brain 
tissue we applied a Biochrome 30 amino acid analyzer. It is a standardized, automated method based 
on separation by ion exchange chromatography followed by post column derivatization using 
ninhydrin. The ninhydrin-amino complex formed was detected by UV/light-absorbance. 
Chromatography uses the different physiochemical properties of the molecules to distinguish the 
compounds based on differences in their distribution between mobile phase and a stationary phase 
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through the column. The compounds are eluted in a specific order, and the time between application 
and elution, called retention time, is used for identification of the compound. The method can be 
applied for different physiological fluids as plasma, CSF and urine (193) and for tissue samples.  
Phenylacetylglutamine, Phenylacetylglycine and Hippuric acid in urine 
For the measurement of phenylacteylglutamine, phenylacetylglycine and hippuric acid we applied 
liquid chromatography tandem mass spectrometry (LC/MS-MS). A mass spectrometer is an 
instrument that can separate charged atoms or molecules according to their mass-to-charge ratio 
(m/z). Ionized molecules flow through a magnetic field and create a fragmentation of ions 
establishing a pattern that serves as a fingerprint of the compound (194, 195). This can be compared 
to known patterns to identify a compound. The use of stable isotope internal standards and tandem 
MS (MS-MS) enhances the sensitivity and accuracy. LC/MS-MS is used for detecting and identifying 
endogenous and exogenous molecules of low concentration in physiological fluids.  
A mass spectrometer system generally consists of 5 main parts:  
 
Figure 11 Mass spectrometry system 
 
Figure 12  Consol for system - MS display Xevo TQ-S Screen.  
Reprint with permission from Waters Corporation, Sweden   
Glutamine synthetase activity in muscle biopsies   
Glutamine synthetase activity was measured by the calorimetric method as described by Minet et al. 
(196). It is a well validated method for the measurement of GS activity in muscles. For further details 
regarding preparation and calculation see supplementary material to paper II.    
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4. SUMMARY OF RESULTS 
Study I 
In this study our focus was to investigate ultrastructural changes in the brain of pigs with ALF induced 
by hepatic devascularization. We found macroscopic differences between the sham and ALF group as 
the ALF group had signs of increased brain water and swelling, flattening of the gyri and narrowing of 
the sulci. Furthermore, electron microscopic evaluation of the three regions frontal cortex, 
cerebellum and brain stem revealed a significantly increased degree of pathological findings with 
regard to edema, neuronal and astrocytic damage and oligodendrocytes/myelin changes in the ALF 
group compared with the sham group. Few inflammatory cells were found, except for focal areas 
with polymorphic nuclear granulocytes around necrotic cells in the ALF group. Signs of disrupted 
blood-brain barrier were seen in the ALF-group.  
Study II 
In this study we intended to explore the effect of Ornithine Phenylacetate (OP) on arterial and brain 
extracellular ammonia and its potential effect on ICP in this model of ALF. We found a significant 
increase in arterial and brain extracellular ammonia in the placebo-treated ALF group that was 
significantly attenuated in the OP-treated ALF group. This effect was seen in both arterial blood and 
brain extracellular fluid. We also observed a significant attenuation in ICP in the OP-treated group. 
The decrease in ICP correlated to the decrease of ammonia in both arterial blood and brain 
extracellular fluid. We found a significant increase in phenylacetylglutamine excreted in urine in the 
OP-treated group compared to placebo-treated ALF pigs, although the increase in 
phenylacetylglutamine in urine did not correlate stoichiometrically to the decrease in arterial 
ammonia.  
Study III 
In this study we conducted a secondary analysis to explore the lack of stoichiometric correlation 
between the decrease in arterial ammonia and the increase in phenylacetylglutamine excreted in 
urine. We found an increase in arterial glycine in the ALF placebo-treated group that was significantly 
attenuated in the OP-treated group. Arterial glycine significantly correlated to arterial ammonia and 
ICP levels published in paper II. Furthermore, the tissue concentration of glycine in brain frontal lobe 
was significantly decreased in the OP treated group compared to the ALF group. Together, these 
findings indicate a possible role for glycine in the ammonia metabolism in this model of ALF. We also 
found a nearly significant increase in the glycine release across the kidneys, which was significantly 
attenuated in the OP treated group, indicating an important role for the kidney in ammonia 
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metabolism. Finally, we found a highly significant increase in phenylacetylglycine in urine in the OP 
treated animals. This suggests that conjugation of phenylacetate to glycine is an important metabolic 
pathway in this model of ALF. This finding provides a mechanistic explanation for the net removal of 
ammonia in OP treated pigs.  
  






A well characterized porcine devascularization model of ALF has been used for this thesis. This model 
presents the cardinal features of human ALF with development of hyperammonemia with typical 
amino acid disturbances, increased ICP, hyperdynamic circulation and coagulopathy within 8 hrs after 
ALF induction (185). It has been validated as a suitable model for the study of interventions in the 
initial phase of ALF as it provides a time frame of 8 hrs for studying the effect of potential new 
treatment concepts (62, 197).  
ALF is a rare disease emphasizing the importance of having reproducible and clinically relevant 
animal models. A large animal model provides a clinical relevant setting for studying the underlying 
pathophysiology, and provides an opportunity to perform intensive care monitoring and provide 
supportive therapy to resemble the clinical setting (198, 199). The use of a large animal model is 
furthermore recommended by the criteria put forward by Terblanche and Hickman, as it enables the 
use of therapies applicable to man (200). Compared to small animal models, the possibility of taking 
multiple blood and extracellular fluid samples allowed us to study the temporal pattern in the course 
of the disease.  
Three strategies for inducing ALF have traditionally been applied – hepatotoxic drugs, different 
degrees of devascularisation and hepatectomy. A devascularization model precludes the 
investigation of potential reversibility, but is on the other hand highly reproducible. In the case of 
acetaminophen models, maintaining a suitable plasma level of drug to induce the liver failure 
without causing complications such as methemoglobinemia is challenging (201). For the study of ALF 
the presence of a disturbed nitrogen metabolism is of pivotal importance as one of the major 
pathophysiological factors in ALF is the development of hyperammonemia. Hyperammonemia is 
highly reproducible in this model in contrast to the paracetmol model proposed by Dabos et al. 
showing an unaffected urea cycle (202). We found an abrupt decrease in urea levels which implies 
that the urea cycle is impaired making the metabolism dependent on alternative pathways. A 
devascularization model is therefore suitable for the study of liver independent metabolism. An 
important notion is, however, the potential effect of residual hepatic vein circulation in this model. 
Although ALF induces an inflammatory response, circulating inflammatory markers have not been 
found in this model. This could be due to the relatively short time frame of the experiment (62).   
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Our main focus has been brain dysfunction and interorgan metabolism of ammonia and amino acids 
in ALF. These pigs develop intracranial hypertension within 8 hrs. Increased ICP has also been 
observed in earlier studies of ALF in pigs induced by devascularization (41). The use of a hepatotoxin 
could potentially confound histological examination of the brain due effects on the BBB (203). In a 
study comparing devascularisation and hepatectomized models, devascularisation models were 
shown to be superior to hepatectomy models in creating an amino acid pattern which resembles 
human plasma amino acids profile (204). 
The current studies included 32 animals. 8 animals (O and P) were included for hypothesis generating 
experiments, leaving 24 animals for the main studies. Due to technical reasons three, one in each 
group, were excluded. Accordingly 21 animals were included in the final data analyses. This is a small 
cohort for performing formal statistics which in turn increases the risk of both type 1 and type 2 
errors. Avoiding type 1 errors is important. Furthermore, the risk of not detecting physiological 
differences also increases with such a small cohort. The use of large animal models for studying ALF is 
of high value, but for ethical reasons the number of animals are reduced. However, less than 7 pigs in 
each study group would not allow us to draw confident conclusions. A substantial sample bank was 
made in order to perform different studies from the same experiment.  
Paper I 
The development of cerebral edema represents a feared complication in ALF, and cerebral herniation 
due to edema is still a major cause of death in ALF (7). Cerebral edema, defined by a net increase in 
brain tissue water content (51), is closely linked with increased ICP (32, 139). Current treatment for 
intracranial hypertension (ICH) includes infusion of hyperosmotic solutions, sedation and 
hypothermia as a promising therapeutic modality (48).   
Brain edema can be of cytotoxic or vasogenic origin, the latter being indicative of a physical 
breakdown of blood brain barrier (BBB). The first studies on ultrastructural changes in coma induced 
by hepatic failure were performed by Martinez et al. and Livingstone et al. Martinez found swollen 
astrocytes in brain biopsies from two patients dying from hepatic coma (205). Livingstone found 
indications of an increased permeability across the BBB (substances such as inulin and trypan blue 
which normally do not cross the BBB) in a rat model of ALF. Furthermore, on electron microscopic 
examination swollen astrocytes especially in pericapillary locations were also found (206). They 
concluded that a vasogenic component contributed in the later stages of ALF. Other studies in 
different animal models have also found indications of increased permeability across the BBB for 
substances normally not entering the brain (60, 207, 208). Kato et al. found marked swelling of the 
perivascular astroglial foot processes, dilatation of the extracellular spaces and endothelial cells with 
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increased numbers of vesicles and vacuoles on electronmicroscopic examination in animals and 
patients with ALF (59, 209). However, in human post mortem frontal cortex biopsies from patients 
dying from ALF they found intact tight junctions between the brain capillary endothelial cells. They 
concluded therefore that brain edema developed primarily due to cytotoxic mechanisms with intact 
BBB (59). A later animal study concluded with edema of both cytotoxic and vasogenic origin (64). The 
type of brain edema seen in ALF has since been debated with studies indicating a mainly, if not solely 
cytotoxic origin (210) on one hand, and studies indicating a mixed mechanism with subtle changes in 
the BBB leading to increased permeability rather than a full breakdown (57, 211) on the other hand.  
The present model of ALF has previously been shown to be a valid model for hyper acute liver failure 
with brain edema and increased ICP (185). Morphological studies of the brain have, however, not 
been performed. In light of the results from the study by Kato et al. we therefore wanted to provide 
a descriptive study by means of electron microscopic examination of brain edema in ALF compared 
to control animals. For the evaluation of the neuropathological changes we applied a semi-
quantitative method introduced by Shaper et al. (190). We evaluated perivascular edema with 
endothelial cell morphology, glia cell morphology and oligodendrocyte morphology. We also looked 
at neuronal damage and the presence of inflammatory cells (microglia). The use of a semiquantiative 
evaluation system allowed us to perform statistical evaluation of the observed changes. We looked 
into the pathological changes in three different regions; frontal lobe, cerebellum and brain stem, and 
we found a significantly higher score for all factors and all regions except for oligodendroglia in 
frontal lobe and purkinje celles (neuronal celles) in cerebellum in the ALF animals compared to sham 
animals.  
Biopsies from the different regions were primarily assessed by light microscopy and regions with 
artefacts were excluded. This initial assessment was not blinded for the investigating pathologist as 
the main purpose was to find representative regions for further evaluation. Regions showing the 
most pronounced changes were consistently selected for further investigation to ensure comparable 
examination between sham and ALF groups. Chosen areas were further prepared for electron 
microscopic examination and then blinded for the investigator.  
We found evidence of severe brain injury including macroscopic edema, cellular swelling and 
necrotic cell death of both neurons and astrocytes. The observation of perivascular edema is in 
accordance with prior histopathological studies (59, 64, 206, 209). Furthermore, damaged 
endothelium with vacuoles and vesicles indicate vasogenic involvement (64). We also observed 
swollen astrocytes and broken projections radiating from the vessel wall ending into the perivascular 
space, presumably astroglial and pericytic processes.  
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This study was designed as a histological examination of brain edema. Electron-microscopic 
examination is a valid method for evaluating the integrity of the BBB. However, previous small animal 
studies have also applied markers as Evans blue, trypan blue, and inulin to assess functionally the 
permeability of the BBB. These substances are normally not transferred into the brain due to tight 
junctions between the brain capillary endothelial cells (BBB). When present in brain tissue, 
indications of increased permeability and potential vasogenic edema are given. Lv et al. found an 
increase in the concentration of Evans blue in brain tissue from T=2 in a model of ALF in mice (212). 
Livingstone found increased permeability for trypan blue, inulin, sucrose and glucose (206), a finding 
confirmed by Zaki (60). Performing such analysis undoubtedly would have added further information 
regarding the BBB permeability in our model. However, for technical reasons, we did not test for BBB 
breakdown by the use of permeability markers.  In addition, apoptotic antibody staining could have 
provided more information regarding the mechanisms for injury to the endothelial cells.  
A discrepancy has been observed between electron-microscopic findings and functional permeability 
measurements of the BBB. In general, a complete breakdown of the BBB has not been found in spite 
of increased permeability of markers. Nevertheless, with improving methods for investigating the 
BBB, subtle changes in tight junction proteins that can increase the permeability to small molecules 
have been found (211). Modulation of the expression of genes coding for tight junction proteins as 
occludin have been reported (213), and claudin-12 has was found to be altered in hyperammonemia 
(214). Increased activity of MMP-9 was found to induce degradation of occludin and claudin-5 in 
different models of ALF and in vitro models (215). Furthermore, transport mechanisms of molecules 
across cell membranes may be altered in hyperammonemia (32, 209, 216). The accepted tenet today 
for brain edema in ALF is therefore primarily a cytotoxic edema with potential vasogenic components 
due to subtle changes in tight junctions, but without a complete disruption of the BBB (57).  
This model of ALF is characterized by a sudden increase in ammonia and brain edema shown by 
increased brain water (62). This part of our study did not allow us to draw conclusions about the 
cause of brain edema seen by histological examination. Still, in this model there is no doubt that 
ammonia is a major contributing factor to the brain edema, as changes in inflammatory state or 
cerebral blood flow have not been observed (62). Increased ammonia leads to compensatory 
increased glutamine production through GS in the astrocytes which culminates in swelling of the 
astrocyte and an edema of cytotoxic origin. Due to the sudden rise in ammonia, compensatory 
mechanisms as extrusion of other osmolytes and decreased CSF production may not manage to 
compensate in the short time aspect of this model. We observed increased ICP from T=2 to T=8 that 
correlated with the ammonia increase. At T=8 the mean arterial ammonia level was approximately 
590 μM in the ALF group. Human studies have shown a correlation between arterial ammonia of 
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more than 150 μM and the incidence of cerebral herniation (CH) (73). The high ammonia level and 
rapid progression to brain edema in this model may not fully correspond to the clinical setting seen 
in human ALF or other animal models. Our histopathological findings could therefore represent 
changes that are attributable to vasogenic edema late in the course of ALF, when an established 
cytotoxic edema is present.  
The histological examination was done at T=8 only. ICP measurements give indirect evidence of the 
presence of brain edema in this model, but our study does not provide any information about the 
type of brain edema at earlier time points than T=8. We therefore do not provide information to 
what time point the edema starts or to what type of edema is present at the different time points. 
For future experiments, a study design with termination points at T= 2, 4 and 6 would therefore be 
preferable to be able to study the temporal pattern of brain edema in this model. Conflicting results 
regarding the order and development of cytotoxic and vasogenic edema have been reported. 
Livingstone et al. interpreted their findings of vasogenic edema as possibly a late stage phenomenon 
(206). Dixit et al. found marked swelling of perivascular astrocytes already at HE grade I in a rat 
galactosamine model of ALF, and from grade III they observed increased permeability for Trypan 
blue, indicative of BBB breakdown (208). Cauli et al. found, using a galactosamine induced ALF rat 
model, vasogenic edema to be the primary event in certain brain regions, followed by a cytotoxic 
edema later in the course of the disease (217). Chavarria found mainly cytotoxic mechanisms using 
MRI in a devascularization model of ALF in the rat (218).  
Earlier studies reporting BBB breakdown in ALF have been criticized for not accounting for the 
terminal phase of brain edema, suggesting that their findings could be affected by hypotension, 
hypoxia and alterations in CBF. A component of hypoxia at T=8 is difficult to completely rule out. 
However, factors such as cerebral perfusion pressure (CPP), arterial oxygen saturation, plasma 
glucose and sodium levels and temperature were all closely monitored to prevent potential 
confounding effects. Mean CPP in the ALF group was 50 mmHg at T=8 during the brain biopsy 
harvesting. This is at the lower limit of recommended CPP (163), and could potentially have caused 
ultrastructural alterations in itself.   
Studies have shown different distributions of edema for different regions in ALF (63, 64). Gove et al. 
found regional differences between forebrain and hindbrain in rats with ALF, with vasogenic 
mechanism being the more important in the hindbrain. Additionally, they found the cerebellum to be 
more susceptible to edema formation (64). Traber et al. found increased brain water in cortical grey 
matter, but not subcortical of pontine white matter or in the cerebellum (63). In the present study 
we focused on ultrastructural changes, rather than brain water measurements. We examined frontal 
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lobe, cerebellum and brain stem. Interestingly we did not observe significant changes in white 
matter, studying purkinje fibers in the cerebellum and myelin in the frontal lobe. In accordance with 
this Horowitz et al. found no uptake of 14-alpha-aminoisobutyric acid in the white matter in rabbits 
with ALF (207). Relating our ultrastructural findings to brain water measurement for different regions 
will be a focus for further studies in this model. Different types of astrocytes are found in grey and 
white matter. This could also have implications for the development of brain edema in liver failure 
(46, 51). Moreover, a prior study in this model showed white matter more responsive to intervention 
(albumin dialysis) than grey matter (62), but further studies are needed to elucidate the mechanisms 
behind this finding.  
Inflammation plays a major role in the development of increased ICP in ALF (12). Studies have also 
shown that proinflammatory cytokines can affect BBB permeability in ALF, and have linked this to 
decreased expression of tight junction proteins (212). Furthermore, brain derived inflammatory 
response, shown by microglia activation has been reported (219). In our study we did not find a 
significantly increased number of inflammatory cells (microglia) in the brains of ALF animals. This 
corresponds to previous studies in this model showing no increase in serum pro-inflammatory 
cytokines in pigs with ALF. Wang et al. showed on electron microscopic evaluation that tight junction 
disruption and increased permeability of the BBB could be prevented by TNF-α inhibitor (220). 
Takada et al. observed a further increased ICP in a hepatotoxin porcine model of ALF, after 
administration of lipopolysaccharides (LPS) (144). The lack of inflammatory response in our model 
could be due to a short time interval.  
The presence of a potential BBB break down in the short time frame of this model makes it clinically 
relevant since treatment options such as hypertonic solutions are dependent on an intact BBB. The 
use of mannitol can be effective in treatment of increased ICP (221). However, patients who do not 
respond to this treatment may have BBB breakdown. Due to the high level and rapid increase of 
ammonia in this model, it may resemble a phase beyond reversibility of the edema, and 
compensatory mechanisms as extrusion of other osmolytes may not be sufficiently effective. This 
study was not designed to study reversibility of brain edema in ALF. Therefore, our data are not 
conclusive as to whether administration of mannitol is of benefit in ALF. An intervention-study 
looking at changes and possible reversibility at T=2, 4 and 6 would add knowledge to this question, 
and is warranted.   
Questions have been raised regarding the total reversibility of hepatic encephalopathy as a metabolic 
syndrome (92, 222, 223). We find severe, neuronal damage on ultrastructural examination in this 
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model of ALF. A vasogenic component in brain edema present in ALF and the presence of neuronal 
damage would suggest a nonreversible factor that may be persisting after liver transplantation.  
We found significant but small differences in the neuropathology analysis between the sham and ALF 
groups and therefore, with such small differences, we did not pursue to study differences between 
ALF and OP groups. The primary purpose of study I was to evaluate brain edema in this model of ALF 
with EM methodology.  
In conclusion, we believe our findings support the concept that vasogenic mechanisms are important 
in the pathogenesis of brain edema in ALF.  
Paper II and III 
Today ammonia is accepted as a primary contributor in the pathogenesis of brain edema in ALF (38, 
224). At present there is no definitive treatment for reducing the ammonia load on the brain, and the 
only definitive treatment option for ALF is emergency liver transplantation. By reducing ammonia, 
brain edema can potentially be prevented or sufficiently reduced giving the liver time to regenerate 
and recover sufficient function to maintain homeostasis and avoid the need for liver transplantation.   
The main finding in the intervention study of Ornithine Phenylacetate (OP) in ALF covered in paper II 
and paper III was a reduction in arterial and brain ammonia that was accompanied by a significant 
reduction in ICP. This observation confirms a strong correlation between ammonia and ICH in ALF 
(38, 73-76). Furthermore, an exploration of potential pathways for ammonia removal in this model 
led us to discover a novel and potentially significant role of glycine in ALF.  
We observed an increase in arterial ammonia reaching 590 μM in the ALF group at T=8. This increase 
was attenuated in the OP treated group, with a maximum ammonia concentration of 365 μM at T=8. 
This is the first study showing ammonia reducing effect of the OP-treatment in ALF. In addition, it 
shows the effectiveness of the treatment in the short time frame of this model displaying very high 
arterial ammonia levels. Together with arterial ammonia levels, we also measured ammonia in brain 
extracellular fluid using microdialysis. There, we found a significant attenuation of ammonia in the 
OP treated group (220 μM in OP treated group vs 500 μM in placebo treated group) confirming an 
ammonia lowering effect also in the brain. The attenuation of plasma ammonia significantly 
correlated with the change in brain extracellular fluid ammonia supporting the fact that systemic 
hyperammonemia is associated with increased concentrations of ammonia in the brain in ALF (83).  
The correlation between increased arterial ammonia and increased ICP has been observed both in 
humans and animal models (70). In the ALF group ICP increased to an average of 18 mmHg at T=8. 
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This increase was prevented by the OP treatment, showing ICP levels not significantly different from 
the sham group. Increased brain water and ICP have previously been shown in this model (62). For 
the present study we did not do brain water measurement. None the less, in a cirrhotic rat model a 
significant reduction in brain water after OP treatment was shown (225). This reduction was 
associated with restored myoinositol/glutamine ratio indicating an adaptive response over time. 
Such response is rather unlikely in the short time frame of this and other models of ALF (126), and in 
the clinical setting of ALF. The exact mechanisms for ICP lowering effect of OP in this model therefore 
need further studies, focusing on repeated measure in the brain of the extracellular domain, using 
microdialysis.  
This model displays a hyperdynamic circulation induced by ALF (185). Systemic hemodynamic 
measurements were undertaken to elucidate whether changes in ICP could relate to hemodynamic 
improvement due to the OP treatment. Significantly increased cardiac index and decreased cerebral 
perfusion pressure (CPP = MAP-ICP) were found in the ALF group compared to the sham group. 
Significant intergroup differences were not found between placebo treated and OP treated animals, 
excluding a cofounding effect of improved systemic and cerebral hemodynamics of OP treatment. 
This allowed us to conclude the attenuation of ICP is independent of CBF, in accordance with a 
previous study in this model (62).  
Brain edema is believed to be mediated by a synergistic effect of ammonia and inflammation 
together with increased CBF in relation to ICP surges (65). Since studies in this model have not 
detected any increased levels of inflammatory markers (62), brain edema has been regarded as 
independent of inflammation. However, in this model the hepatic veins are left intact making a 
distribution of inflammatory cytokines from the damaged liver possible.  
The strong correlation between ammonia and ICP in ALF suggests that ammonia lowering treatment 
is of pivotal importance in the treatment of ALF. Treatments aiming at reducing the production of 
ammonia in chronic liver failure, as non-absorbable antibotics and disaccharides, have shown 
beneficial effect for secondary prophylaxis in cirrhosis (226). In ALF the abrupt, complete failure of 
ammonia removal by the liver leads to an acute overload, and the ammonia production overwhelms 
the removal by treatments such as lactulose. Indeed, these treatments for hyperammonemia have 
not proved beneficial effect in ALF (173). Moreover, studies have shown that the gut derived 
ammonia in large part is due to glutamine breakdown in the short bowel instead of luminal content 
derived ammonia from the colon (96, 109). This would imply that modulating the glutamine level is 
important to decrease the overall ammonia level in patients with liver failure. Reducing ammonia by 
means of increasing removal rather than decreasing production has therefore gained renewed 
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interest. Giving L-Ornithine L-Aspartate has been shown to reduce arterial ammonia by providing 
increased glutamine for detoxification and increasing the residual capacity for urea synthesis in the 
liver in patients with cirrhosis (170). The results have, however, been conflicting and a number of 
studies have never been published. The immediate effect of LOLA is to increase the physiological 
ammonia carrying effect of glutamine by providing substrates for glutamine synthesis. Together with 
this, an increased residual effect of urea synthesis can remove more ammonia (174). In ALF, with 
little or no rest function of periportal urea synthesis or perivenous glutamine synthesis, the effect of 
LOLA is dependent on extrahepatic glutamine synthesis. As glutamine is not being removed from the 
circulation, concerns have been raised regarding a potential rebound hyperammonemia due to the 
action of the enzyme glutaminase primarily in the intestines and the kidneys, which has also been 
observed in patients treated with LOLA (183). Indeed the only randomized controlled trial for LOLA in 
ALF could not find any reduction in arterial ammonia or outcome (176). In ALF, with little or no 
remaining liver function, extrahepatic compensatory mechanisms for ammonia removal are needed. 
Net removal of glutamine from the circulation is pivotal to prevent a rebound hyperammonemia 
(183).  
In our model we found highly significantly increased arterial ammonia together with a significant 
decrease in the urea levels indicating an abrupt and fulminant deterioration of the nitrogen handling 
in the liver. This makes this mode suitable for studying extrahepatic metabolism of ammonia. We 
focused our investigation on the role of the muscle (paper II) and the kidneys (paper III) in 
metabolism of ammonia and related amino acid.   
Means of reducing arterial ammonia by modulating its interorgan metabolism and providing non-
urea dependent pathways for removal have been explored both in liver failure (182) and in isolated 
enzymatic disorders like UCD (179). The use of alternative pathway therapy such as phenylacetate 
and benzoate has shown positive effect on morbidity and mortality in patients with UCDs (181). 
UCDs and ALF share one important feature - the presence of brain edema in hyperammonemia. UCD 
patients have, however, no liver insufficiency other than metabolism of nitrogen and ammonia, 
confirming the important role of ammonia in brain edema. 
In cirrhosis glutamate deficiency has been reported (96). We observed a significantly lower glutamate 
level in ALF animals compared to sham animals. This was restored when given OP. Decreased 
glutamate has also been reported in patients with ALF and in prior studies in this model (107, 114) 
providing a rationale for giving ornithine. Ornithine provides a substrate for glutamate through 
transamination (227). Increasing the glutamate synthesis is reasonable in order to prevent a 
potential depletion of branched chain amino acids (BCAA) from muscle (228). We found increased 
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ornithine in both plasma and muscle showing an uptake across the muscle. A lack of glutamate 
transporters in muscle cells has been reported. Therefore, indirectly increasing muscle glutamate 
using ornithine was required.  
Patients suffering from UCD, without intrinsic liver disease, have upregulated perivenous GS and 
therefore phenylacetate treatment alone in these patients is enough to lower blood ammonia levels. 
In our study ALF pigs demonstrated an increase in blood glutamine levels. However, in a pilot phase 
of this study phenylacetate given alone failed to lower blood ammonia. Neither did ornithine alone 
lower ammonia as might be suggested if the ammonia removal effect would be the glutamine 
production alone. Therefore the combination of ornithine and phenylacetate induces a synergistic 
effect that lowers and removes ammonia. Hence, the subsequent studies evaluated the effect of 
combined ornithine and phenyalacetate treatment (OP). 
Interorgan metabolism of ammonia is given by the distribution of glutamine synthetase and 
glutaminase (93). The liver contains both enzymes and controls the ammonia homeostasis in the 
normal state resulting in no net increase in systemic ammonia in spite of varying nitrogen load from 
the portal blood (95, 96). In ALF, GS activity in muscle becomes of vital importance due to its overall 
mass. Increased glutamine synthesis can increase detoxification of ammonia in liver failure, and 
increased activity and expression of the GS enzyme has been found in animal models treated with 
LOLA (72). In accordance with this, we found a trend toward increased GS activity, although not 
significant, emphasizing the capacity of muscle GS activity increase in this short time frame. We did 
not find increased enzyme expression which would be unlikely due to the short time span of this 
model. Glutaminase is abundant in intestines and kidneys (102). By administration of phenylacetate a 
potential rebound hyperammonemia due to glutaminase activity in the kidneys and intestines was 
prevented. This was also confirmed in a cirrhotic model over five weeks (225).  
In this study we found a significantly increased arterial glycine level in ALF animals that was 
significantly attenuated in the OP treated group. We also found a significant correlation between 
glycine and ammonia. Glycine is an important ammoniagenic amino acid (229), which is increased in 
ALF (107). Glycine metabolism can generate free ammonia through both glycine oxidase and the 
glycine cleavage reaction (230). Increased arterial glycine has been observed both in a paracetamol 
induced ALF animal model (202) as well as in patients suffering from fulminant hepatic failure (107). 
In addition, an increase in extracellular levels of glycine in the brain has been demonstrated in ALF 
rats (91, 231), supporting a role for glycine in the onset of hyperammonemia and HE. Increased 
glycine in the brain is associated with metabolic brain disturbances as hyperglycinemic 
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encephalopathy, a disease resulting in developmental abnormalities in children(232). Glycine is also 
an important inhibitory neurotransmitter in the central nervous system.   
Our data do not provide a definitive explanation to the origin of the increased glycine in ALF. Glycine 
is produced through three different mechanisms as outlined in figure 14. Briefly, serine, alanine and 
the glycine cleavage complex can increase glycine. We did not find differences in serine that could 
confirm serine as origin of the increased glycine in this model. There is reason to discuss whether 
increased glycolysis could lead to increased serine used for glycine synthesis in this model. Plasma 
levels of serine do not necessarily reflect the overall balance of serine. This could be elucidated if 
studying serine in other compartments. Alanine can increase glycine through transamination with 
pyruvate. We do see increased alanine in the OP group, but not in the placebo treated ALF group, 
which adds further questions to the origin of the observed increased glycine. Alanine serves an 
important role for transport of ammonia between muscle and liver, and provides also a link between 
the nitrogen and carbohydrate metabolism (glucose-alanine cycle). Alanine has also been shown to 
be an alternative to glutamine synthesis for ammonia removal in the brain (233) . The glycine 
cleavage complex mainly works in a catabolic way, liberating ammonia (230). Therefore, minimizing 
the substrate for this reaction provides a reasonable explanation for the removal of ammonia.  
OP treatment attenuated arterial glycine. Decreased arterial glycine and ammonia levels were 
accompanied by decreased brain tissue glycine from frontal lobe. Our results do not provide 
indications as to whether this is blood mediated or results from modulated production in the brain. 
Further microdialysis studies could shed light on this. We also found a significant correlation between 
arterial glycine and ICP measurement. Based on our results we cannot conclude whether glycine 
affects brain edema through ammoniagenesis or directly affects the osmolarity in the astrocytes. 
These pathophysiological pathways merit to be further investigated.   
Our data suggest that the kidneys are important in the metabolism of glycine in this model of ALF. 
Both the increase in the ALF group and the attenuation in the OP treated group seem to be mediated 
by the kidneys when studying venous arterial differences across portal drained viscera, hind leg and 
kidneys. We found significant differences only across the latter. In this devascularized model of ALF it 
would be reasonable to assume that the kidneys are important metabolic organs in the absence of a 
functional liver. This necessitates available enzymatic machinery for both glycine production and the 
conjugation with phenylacetate. The conjugation enzyme is mainly found in the liver but is also 
present in the kidneys (234). We did not measure activity of enzymes in this study, which could have 
provided us with further mechanistic insight.  
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In the OP treated group we found no removal of glutamine. Glutamine and alanine can induce 
negative feedback inhibition on the GS-enzyme (235). In this model a systemic inhibition of GS is 
likely as the produced glutamine is not removed and an increase in arterial alanine is observed. This 
can potentially stimulate other ammonia removing pathways, including glycine mediated removal of 
ammonia. The removal of ammonia is therefore likely to have taken place in the ammonia fixating 
step of GDH producing glutamate instead of the GS reaction giving glutamine. The GDH reaction is 
reversible and its direction is set by the concentration of its substrates and products. This study sheds 
light on the potential ammonia removing capacity of glycine in liver failure, but further studies are 
warranted.  Removal of glycine is already an accepted treatment in UCD patients by the use of 
benzoate (179). Benzoate has been evaluated in one clinical study in cirrhosis and was found to be as 
effective as lactulose in reducing hyperammonemia (182). 
The lack of stoichiometry between ammonia removal and increased phenylacetylglutamine in urine 
in paper II prompted further investigation on alternative excretion pathways. Known pathways for 
non-urea dependent removal of nitrogen include phenylacetyglutamine, phenylbutyrylglutamine, 
phenylacetylglycine (236) and hippuric acid. As we did not administer benzoate, an induction of the 
hippuric acid pathway seemed unlikely. Indeed, we found no increase in the excretion of hippuric 
acid in the OP treated group. Further analysis showed uptake of phenylbutyrate from the intestines 
and conversion to systemic phenylacetate across the enterocytes (β-oxidation) (237). We did, 
however, not find sufficient amounts of phenylacetylglutamine in plasma or tissue that could explain 
our observations as purely a time related excretion deficit.  
 
 
Figure 13 Arterial phenylbutyrate and phenylacetate. Phenylbutyrate is converted to phenylacetate by β-oxidation in 
enterocytes. 
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The lack of glutamine removal suggested another amino acid substrate for the conjugation reaction. 
In light of the results from paper III the proposed mechanism of ammonia reducing effect by OP 
seems to be confounded by the conjugation of phenylacetate to glycine. We found highly increased 
excretion of phenylacetylglycine in the OP treated group, and significantly more than 




Figure 14  Influence of OP on glutamine and glycine metabolic pathways. Ammonia can be removed following reactions 
with glutamine synthetase (1) and glutamate dehydrogenase (2). Ornithine administration stimulates glutamate 
production which in turn generates glutamine (via glutamine synthetase) and glycine (via serine). Glutamine and glycine 
metabolism can lead to ammonia generation via glutaminase (3) and glycine oxidase (4) and glycine cleavage complex 
(5), respectively. Administration of phenylacetate leads to an increase in conjugation with both glutamine (generating 
phenylacetylglutamine) and glycine (generating phenylacetylglycine) precluding the generation of glutamine and glycine-
derived ammonia and preventing an ammonia rebound.  
Reprint with permission: Kristiansen RG, Rose CF, L-Ornithine Phenylacetate reduces ammonia in pigs with acute liver failure 
through phenylacetylglycine formation: a novel ammonia-lowering pathway, Am J Physiol Gastrointest Liver Physiol. 
2014;307(10):G1024-31 
 
Studies of OP treatment in liver failure have consistently shown ammonia reduction (238, 239), 
although further mechanistic studies are warranted (227). One human study has been conducted, 
showing OP to be well tolerated and able to decrease ammonia (240). A study using phenylbutyrate 
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alone in liver failure observed a reduction in ammonia and HE events in cirrhosis (241). However, 
amino acid profile or the presence of non-urea dependent urinary excretion products were not 
presented. Further mechanistic data is therefore warranted.   
Today phenylacetate is given intravenously, and not intraduodenally as in this study. We did not 
conduct recovery analysis in order to account for the ornithine and phenylacetate given, as was done 
in the study by Dadsetan et al (227). Calculating recovery rate for ornithine and phenylacetate could 
improve the dosing of the drug in clinical studies and elucidate potential excretion delay that could 
result in adverse effects. Also, as ALF patients often present with accompanying renal failure, the 
excretion with impaired renal function needs to be evaluated. Studies have shown that plasma levels 
of phenylacetylglutamine are reduced by hemodialysis (242, 243).   
  





ALF may cause severe, irreversible brain damage. Ultrastructural examination of different brain 
regions in pigs with ALF support the concept that vasogenic brain edema plays an important role in 
the development of intracranial hypertension in ALF.  
A strong correlation between increased arterial ammonia and ICH exists, and definite treatment for 
hyperammonemia is still an unmet clinical need. The administration of OP to pigs with ALF 
successfully reduces arterial and extracellular brain ammonia levels and prevents any increase in ICP.  
The ammonia removal is mediated through increased removal of glycine in this model. We provide 
experimental evidence for a novel ammonia-removing pathway via glycine that is active in the 
kidneys in pigs with ALF.  
OP treatment might be a significant step forward in the treatment of patients suffering from ALF. 
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